The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis

Breast Cancer Research and Treatment

Volumn 148, Issue 3, 2014, Pages 467-476

  Ibrahim, Ezzeldin M ^a   Al Foheidi, Meteb E ^b   Al Mansour, Mubarak M ^b   Kazkaz, Ghieth A ^a  

^a International Medical Center   (Saudi Arabia)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Breast cancer; CD8; FOXP3; Lymphocyte infiltrates; Prognosis; Survival

Indexed keywords

ANTHRACYCLINE; ESTROGEN RECEPTOR; FORKHEAD TRANSCRIPTION FACTOR; TAXANE DERIVATIVE; TRASTUZUMAB; FOXP3 PROTEIN, HUMAN; TUMOR MARKER;

BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PHENOTYPE; PREDICTIVE VALUE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; BIOSYNTHESIS; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; META ANALYSIS; PATHOLOGY; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR RECURRENCE;

BIOMARKERS, TUMOR; CD8-POSITIVE T-LYMPHOCYTES; DISEASE-FREE SURVIVAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84912011347     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3185-2     Document Type: Review

References (37)

1. Zitvogel L, Kepp O, Kroemer G (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8:151–160. doi:10.1038/nrclinonc.2010.223
2. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G (2008) The anticancer immune response: indispensable for therapeutic success? J Clin Investig 118:1991–2001. doi:10.1172/JCI35180
3. Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, Muggia F, Symmans WF (2001) Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 7:3025–3030
4. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203–213. doi:10.1056/NEJMoa020177
5. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964. doi:10.1126/science.1129139
6. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29:1093–1102. doi:10.1038/onc.2009.416
7. Whitford P, Mallon EA, George WD, Campbell AM (1990) Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer. Br J Cancer 62:971–975
8. Nixon AJ, Schnitt SJ, Gelman R, Gage I, Bornstein B, Hetelekidis S, Recht A, Silver B, Harris JR, Connolly JL (1996) Relationship of tumor grade to other pathologic features and to treatment outcome of patients with early stage breast carcinoma treated with breast-conserving therapy. Cancer 78:1426–1431. doi:10.1002/(SICI)1097-0142(19961001)78:7<1426::AID-CNCR8>3.0.CO;2-I
9. Droeser R, Zlobec I, Kilic E, Guth U, Heberer M, Spagnoli G, Oertli D, Tapia C (2012) Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. BMC Cancer 12:134. doi:10.1186/1471-2407-12-134
10. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264–271. doi:10.1038/modpathol.3800528
11. Lakhani SR (1999) The pathology of familial breast cancer: morphological aspects. Breast Cancer Res 1:31–35
12. Tamiolakis D, Simopoulos C, Cheva A, Lambropoulou M, Kotini A, Jivannakis T, Papadopoulos N (2002) Immunophenotypic profile of tumor infiltrating lymphocytes in medullary carcinoma of the breast. Eur J Gynaecol Oncol 23:433–436
13. Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, Foulkes WD (2011) Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology 58:1107–1116. doi:10.1111/j.1365-2559.2011.03846.x
14. Ibrahim EM, Al-Foheidi M, Al-Mansour MM, Kazkaz GA, Yunus TE (2014) The prognostic and predicting roles of tumor-Infiltrating lymphocytes in breast cancer: a meta-analysis. The Open Breast Cancer J 6:9–19
15. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. doi:10.1186/1745-6215-8-16
16. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834
17. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558. doi:10.1002/sim.1186
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. doi:10.1136/bmj.327.7414.557
19. Dersimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
20. Donders AR, Van Der Heijden GJ, Stijnen T, Moons KG (2006) Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 59:1087–1091. doi:10.1016/j.jclinepi.2006.01.014
21. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
22. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101
23. Kreike B, Van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, Van De Vijver MJ (2007) Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9:R65. doi:10.1186/bcr1771
24. Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO (2012) CD8 + lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 14:R48. doi:10.1186/bcr3148
25. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, De Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart MJ, Sotiriou C (2013) Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: bIG 02-98. J Clin Oncol 31:860–867. doi:10.1200/JCO.2011.41.0902
26. West NR, Kost SE, Martin SD, Milne K, Deleeuw RJ, Nelson BH, Watson PH (2013) Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer 108:155–162. doi:10.1038/bjc.2012.524
27. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS (2014) Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. J Clin Oncol. doi:10.1200/JCO.2013.55.0491
28. Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, Earl HM, Poole CJ, Hiller L, Dunn JA, Bowden SJ, Twelves C, Bartlett JM, Mahmoud SM, Rakha E, Ellis IO, Liu S, Gao D, Nielsen TO, Pharoah PD, Caldas C (2014) Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol 25:1536–1543. doi:10.1093/annonc/mdu191
29. Chen Z, Chen X, Zhou E, Chen G, Qian K, Wu X, Miao X, Tang Z (2014) Intratumoral CD8(+) cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. PLoS One 9:e95475. doi:10.1371/journal.pone.0095475
30. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25:1544–1550. doi:10.1093/annonc/mdu112
31. Rubbert A, Manger B, Lang N, Kalden JR, Platzer E (1991) Functional characterization of tumor-infiltrating lymphocytes, lymph-node lymphocytes and peripheral-blood lymphocytes from patients with breast cancer. Int J Cancer 49:25–31
32. Bertucci F, Finetti P, Cervera N, Maraninchi D, Viens P, Birnbaum D (2006) Gene expression profiling and clinical outcome in breast cancer. OMICS 10:429–443. doi:10.1089/omi.2006.10.429
33. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121:2750–2767. doi:10.1172/JCI45014
34. Verbrugge I, Johnstone RW (2012) Regulating the TRAIL of destruction: how A20 protects glioblastomas from TRAIL-mediated death. Cancer Discov 2:112–114. doi:10.1158/2159-8290.CD-11-0350
35. John LB, Kershaw MH, Darcy PK (2013) Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology 2:e26286. doi:10.4161/onci.26286
36. Kershaw MH, Devaud C, John LB, Westwood JA, Darcy PK (2013) Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. Oncoimmunology 2:e25962. doi:10.4161/onci.25962
37. Disis ML, Coveler AL, Higgins D, Fintak P, Waisman JR, Reichow J, Slota M, Childs J, Dang Y, Salazar LG (2014) A phase I trial of the safety and immunogenicity of a DNA-based vaccine encoding the HER2/neu (HER2) intracellular domain in subjects with HER2+ breast cancer. ASCO Meet Abstr 32:616